The purpose of this phase I/II study is to evaluate the safety, pharmacokinetics and antiviral activity of an investigational immune globulin product (HIVIG) when given to HIV-infected children. At CHOP, we have enrolled 4 children into this study during the past year. Nationwide, this study has completed its enrollment of 30 children. Data collection and analysis are ongoing.
Showing the most recent 10 out of 455 publications